Twenty-two RCTs (n=6,329) were included in the review. There were some discrepancies between the text and tables.
One RCT compared olanzapine and ziprasidone and found the olanzapine group had significantly greater increases in HbA1c (p<0.05). A second RCT showed a significantly higher level of fasting glucose in the olanzapine group compared with haloperidol, clozapine or risperidone (p<0.02). A third trial found no significant inter-group difference, but a significant decline in HbA1c in the haloperidol and not the quetiapine group.
No other significant differences between any of the antipsychotic treatment groups were reported by any RCT for any glucose parameter.